While the assessing of the direct impact of leachables on patient safety will be a well-understood and a well-managed process in 2015, the assessment of secondary interactions will still be very much a work in progress, says Dr. Dennis Jenke, Baxter

Two members of Catalent's Respiratory, Analytical and Biotechnology Group will participate in the Parenteral Drug Association West Coast Chapter’s panel discussion titled “Challenges and Best Practices in Extractable and Leachables.”